Comparison of Anticonvulsant Effects of Combined Regimens of Gabapentin and Verapamil with their Individual Effects

Authors

  • Itefaq Hussain Qureshi
  • Shahbana Usman Simjee

Keywords:

Antiepileptic drugs, Phenytoin, Gabapentin, Verapamil , Pentylenetetrazole

Abstract

Objective: To evaluate and compare in-vivo anticonvulsant effects of combined regimens of gabapentin and verapamil with
their individual effects on kindled model of epilepsy in mice.
Materials and Methods: This experimental study was carried out in H.E.J. Research Institute of Chemistry, International
Center for Chemical and Biological Sciences, University of Karachi, from May 2009 to July 2011.Gabapentin (GBP) and
Verapamil (VP) were used as tested drugs both as combined regimens as well as individual drugs, Phenytoin was used as
reference drug. Kindling was produced by repeated administration of Pentylenetetrazole in a dose of 50 mg/kg by subcutaneous
route every 48 hours for 20 days. Three doses of Gabapentin from 100 mg/kg to 300 mg/kg and three doses of Verapamil from
10 mg/kg to 30 mg/kg in combination regimens and individual drugs were administered by intraperitoneal route. Phenytoin
was administered by intraperitoneal route in a dose of 50 mg/kg. Gabapentin, Verapamil and Phenytoin were administered once
daily, however, on the day of Pentylenetetrazole treatment, the tested and reference drugs were injected 40 minutes before
injecting Pentylenetetrazole.The anticonvulsive effects of combined regimens of tested drugs were compared to their individual
effects as well as to reference drug Phenytoin.
Results:Combination regimens of GBP and VP demonstrated dose dependent anti- seizure effects up to 100%. The different
doses of combined regimens of GBP and VP demonstrated anti-seizure effects which were superior to their individual effects.
Conclusion:Combination regimens of gabapentin and verapamil showed synergistic effects which were superior to their
individual effects on kindled model of epilepsy in mice.

References

W.H.O, IBE, ILAE. Global Campaign Against Epilepsy, Atlas, 2005

Khatria A, Iannacconea ST, Ilyas MS, Abdullah BM, Saleem S. Epidemiology of epilepsy in Pakistan: Review of literature. J Pak Med Assoc 2003; 53(12): 594-7

Sheerani M. Development of a comprehensive epilepsy surgery program in Pakistan. J. Pak. Med Assoc 2005;55 (1):32-7

Annegers JF, Rocca WA, Hauser WA. Causes of epilepsy: contributions of the Rochester epidemiology project. Mayo ClinProc1996;71(6):570-5

Khosravani H, Zamponi GW. Voltage-gated calcium channels and idiopathic generalized epilepsies. Physiol Rev, 2006;86(3): 941-66

Khosravani H, Altier C, Simms B, Hamming KS, Snutch TP, Mezeyova J et al. Gating effects of mutations in the Cav3.2 T-type calcium channelassociated with childhood absence epilepsy. J Biol Chem 2004;279(11): 9681-4

Banerjee PN,Pilippi D, Allen Hauser WThe descriptive epidemiology of epilepsy-a review. Epilepsy Res 2009; 85:31-45

McTague A, Appleton R. Treatment of difficult epilepsy. Arch Dis Child 2011;96(2):200-4

Summers MA, Moore JL, McAuley JW. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 2004;38(10): 1631-4

Wahab A, Albus K, Gabriel S, Heinemann U. In search of models of pharmaco-resistant epilepsy. Epilepsia 2010;51(3): 154-9

Dichter MA. Innovative clinical trial designs for future antiepileptic drugs.Epilepsia2007;48 (1): 26-30

Goa KL, Sorkin EM Gabapentin: A review of its pharm- acological properties and clinical potential in epilepsy. Drugs 1993;46(3):409-27

Beydoun A, Fakhoury T, Nasreddine W, Abou-Khalil

B. Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. Epile- psia 1998; 39(2):188-93

Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, Gabap- entin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271(10): 5768-76

Iannetti P, Parisi P, Spalice A, Ruggieri M, Zara F. Addi- tion of Verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res 2009; 85(1): 89-95

Iannetti P, Spalice A, Parisi P. Calcium-channel blocker Verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005;46(6): 967-9

Wurpel JN, Iyer SN. Calcium channel blockers verapamil and nimodipine inhibit kindling in adult and immature rats. Epilepsia 1994;35: 443-9

Suman Yadav, Madhu G. Tapadia.Neurodegeneration Caused by Polyglutamine Expansion Is Regulated by P-Glycoprotein in Drosophila melanogaster Genetics, 2013 195: 857-70

Giordanetto F, Knerr L, Wållberg A. T-type calcium channels inhibitors: a patent review. Expert Opin Ther Pat 2011;21(1):85-101

Fletcher CF, Lutz CM, O'Sullivan TN, Shaughnessy JD Jr, Hawkes R, Frankel WN et al.Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 1996;87(4): 607-7

Lerche H, Jurkat-Rott K, Lehmann-Horn F. Ion channels and epilepsy. Am J Med Genet 2001;106: 146–59.

Nicholas AS, Dlugos DJ. Treatment of refractory status epilepticus: literature review and a proposed protocol. Pediatric neurology 2008;38(6): 377-90

Stefani A, Spadoni F, Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neurophar- macol1998;37(1): 83-9

Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. PharmacolTher 2001; 90(1): 21-34

Macdonald RL, Kelly KM. Mechanisms of action of currently prescribed and newly developed antiepileptic drugs. Epilepsia 1994;35 (4):S41-S50

Macdonald RL, Kelly KM. Antiepileptic drug mechani- sms of action. Epilepsia 1995;36 (2):S2-S12

Mulley JC, Scheffer IE, Petrou S, Berkovic SF. Channe- lopathies as a genetic cause of epilepsy. Curr Opin Neu- rol 2003;16(2): 171-6.

Stephen, Linda J, Martin J. Brodie. Pharmacotherapy of epilepsy. CNS drugs 2011;25(2): 89-107

Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al.ILAE treatment guide- lines: evidence-based analysis of antiepileptic drug effi- cacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7): 1094- 1120

Graeme SJ. The mechanisms of action of gabapentin and pregabalin. Current opinion in pharmacology 2006; 6(1): 108-13

Steve WH. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999;40(5): S2-S10

Beydoun A, Fakhoury T, Nasreddine W, Abou-Khalil B. Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. Epilep- sia 1998;39(2):188-93

Gracia-Fleta F, Medrano-Martínez V, Castaño-Pérez MD, Hernández-Lorido R, Mañes R. Gabapentin in 50 patients with epilepsy .Revista de neurologia 2000;32(1): 45-9

Eugene R R. Advances in the pharmacotherapy of epilepsy. Epilepsia1993;34(5): S9-S16

Chadwick, DW. A double-blind trial of gabapentin mon- otherapy for newly diagnosed partial seizures. Neurology 1998;51(5): 1282-8

Downloads

Published

2016-06-06

How to Cite

Qureshi, I. H. ., & Simjee, S. U. . (2016). Comparison of Anticonvulsant Effects of Combined Regimens of Gabapentin and Verapamil with their Individual Effects. Journal of Bahria University Medical and Dental College, 6(2), 110–115. Retrieved from https://jbumdc.bahria.edu.pk/index.php/ojs/article/view/176

Issue

Vol. 6 No. 2 (2016): Volume 6 Issue 2

Section

Original Articles

License

Copyright (c) 2016 Itefaq Hussain Qureshi, Shahbana Usman Simjee

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0